Navigation Links
Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
Date:8/13/2007

Prognostic factors commonly used by clinicians to assess men with prostate cancer do not adequately predict survival outcomes in Asian men living in America, according to the first comprehensive ethnic analysis of Asian-American men with prostate cancer. Published in the September 15, 2007 issue of CANCER, a peer-reviewed journal of the American Cancer Society, the study showed that compared to white men, most Asian ethnic groups except South Asians paradoxically have better outcomes despite having worse prognostic profiles at the time of diagnosis. The study is the first to report prostate cancer survival data for Korean, South Asian and Vietnamese men living in the U.S.

In the U.S. in 2007, over 218,000 men are expected to be diagnosed with prostate cancer and over 27,000 will die. Established prognostic factors include age, summary stage, primary treatment, histologic grade, socioeconomic status, and year of diagnosis. Epidemiologic studies have identified racial differences in incidence and mortality, with African-American men being at greater risk than other races. Asian-American men as a single, ethnic group have the lowest incidence of disease and the lowest mortality rate. The reasons for these racial differences remain poorly studied.

In particular, the risk among different Asian ethnicities is poorly understood, in part, because most studies have aggregated all Asians into a single racial category, ignoring the diverse ethnicities that make up Asia. The few that have tried to analyze by Asian ethnicity have typically analyzed only a few ethnicities, missing significant Asian-American ethnic populations in the process. Interestingly, the data to date show that compared to non-Hispanic white Americans, some Asian ethnicities, such as Japanese-Americans, have higher survival rates, despite worse clinical disease, whereas others, such as Filipino-Americans, have worse survival rates. However, South Asians e.g., Indians, Pakistanis Bangladesh, etc. who represent the third largest Asian subgroup in America, have never been studied for prostate cancer.

Dr. Anthony Robbins of the California Cancer Registry in Sacramento, and co-investigators compared prognostic factors and survival rates of 116,916 men (108,076 whites and 8,840 Asians from the six largest represented Asian ethnicities - Chinese, Filipino, Japanese, Korean, South Asian, and Vietnamese) diagnosed with prostate cancer.

Dr. Robbins and his coauthors found that for each Asian ethnic subgroup, prognostic risk profiles were worse compared to whites. For example, all Asian ethnicities were more likely to have more advanced disease and use non-curative therapies. However, for all Asian ethnicities except South Asians, survival rates were equal to or better than whites. Japanese-Americans, for example, had significantly lower hazard ratio compared to non-Hispanic white Americans (34% lower). In contrast, South Asian-Americans had significantly higher hazard ratio compared to non-Hispanic white Americans (40% higher).

The study should help physicians more accurately apply prognostic factors to their prostate cancer patients. The authors conclude, these results argue that traditional prognostic factors for survival from prostate cancer (stage, grade, treatment, age, year of diagnosis, and socioeconomic status), do not explain why most Asian men have better survival compared to whites, but they do explain the poorer survival of South Asian men compared to whites.


'/>"/>

Contact: Amy Molnar
amolnar@wiley.com
John Wiley & Sons, Inc.
Source:Eurekalert

Related medicine news :

1. Conventional pap smears techniques to detect cervical cancer are here to stay
2. Are Conventional Tests for Heart attacks Reliable?
3. Paramedics save more lives following unconventional rules
4. Coronal Multiplanar Reformatted Images to Replace the Conventional Ones
5. Nitiol Stents A Better Alternative for the Conventional Stents
6. New Laparoscopic Surgery to Correct Vaginal Vault Prolapse Is Effectual Than the Conventional Surgery
7. Alternative to the Conventional Seizure Treatment
8. No Health Benefits from Organic Milk Compared to Conventional Milk
9. Unconventional Hospital Costs For Children Affected By Flu
10. Study Challenges Conventional Treatment of Traumatic Brain Injury
11. Dental x-rays to prognosticate heart attacks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... In 1987, McDaniel & ... years in business this year, and they’re marking the milestone by undertaking a ... their patients. , It stands to reason that, given the central importance ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... has received a three-year grant totaling $975,000, renewing its funding from the Health ... Human Services. , This funding marks, the fourth time the HRSA administration has ...
(Date:8/16/2017)... ... August 16, 2017 , ... SGNA Standards ... after every reprocessing cycle, both between patient procedures and before storage, is a ... is as important to the prevention of disease transmission and nosocomial infection as ...
(Date:8/16/2017)... ... August 16, 2017 , ... Connexion Point, a technology-enabled ... list for the fourth consecutive year. With 197% revenue growth over the ... the nation’s fastest growing companies. , Previous honors include ranking 86th on ...
(Date:8/16/2017)... TX (PRWEB) , ... August 16, 2017 , ... ... the United States, named Dr. Douglas J. Harrison, as the new Medical Director of ... be the new facility Medical Director of our Sienna Plantation location,” said Dr. Michael ...
Breaking Medicine News(10 mins):
(Date:7/31/2017)... Tenn. , July 31, 2017 Three Tru-D SmartUVC ... Yongsan, South Korea . Tru-D, short for "Total Room ... and operating rooms after an environmental services (ES) professional cleans the area ... ... "Although the ...
(Date:7/27/2017)... EXTON, Pa., July 27, 2017  West Pharmaceutical Services, ... financial results for the second-quarter 2017 and updated financial ... Second-Quarter 2017 Highlights Reported ... 2.5% over the prior-year quarter. Net sales at constant ... 2017 reported-diluted EPS was $0.51, compared to $0.60 in ...
(Date:7/25/2017)... BARCELONA, Spain and CAMBRIDGE, Massachusetts ... SOM Biotech, specializing in repurposing drugs to treat rare nervous ... Therapeutics Inc. to clinically develop and market the drug SOM0226 ... reached, the drug achieved very promising results in a Phase ... A new office in the United ...
Breaking Medicine Technology: